Abstract
The chemokine stromal-derived factor-1alpha (SDF-1alpha) and its receptor CXCR4 are critically involved in directional migration and homing of plasma cells in multiple myeloma. Here, we show that the expression of SDF-1alpha and CXCR4 was significantly down-regulated in patients treated with thalidomide (n=10) as compared to newly diagnosed MM patients (n=31) and MM patients treated with other drugs (n=38). SDF-1 alpha and CXCR4 expression was also significantly decreased in a RPMI 8226 cell line treated with 10 and 20micromol/L of thalidomide. Our findings indicate that thalidomide therapy induces down-regulation of CXCR4 and its ligand SDF-1alpha in multiple myeloma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Angiogenesis Inhibitors / therapeutic use*
-
Cell Line, Tumor
-
Chemokine CXCL12 / genetics
-
Chemokine CXCL12 / metabolism*
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Flow Cytometry
-
Gene Expression / drug effects*
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / metabolism
-
Multiple Myeloma / pathology
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Receptors, CXCR4 / genetics
-
Receptors, CXCR4 / metabolism*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Thalidomide / therapeutic use*
Substances
-
Angiogenesis Inhibitors
-
CXCL12 protein, human
-
CXCR4 protein, human
-
Chemokine CXCL12
-
RNA, Messenger
-
Receptors, CXCR4
-
Thalidomide